G6PD deficiency

Introduction to G6PD Deficiency

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a genetic disorder caused by mutations in the G6PD gene located on the X chromosome, affecting the body's ability to produce the G6PD enzyme. This enzyme plays a crucial role in protecting red blood cells from oxidative damage. The condition primarily affects males and is more prevalent in populations from Africa, the Middle East, and Asia. In Vietnam, it is commonly found among ethnic groups such as the Muong, Thai, and Dao.

Prevalence: Globally, an estimated 400 million people have G6PD deficiency. In Vietnam, approximately 4 out of every 1,000 newborns are affected by this condition.

• Semi-Automated Solution
• Product name: Neonatal G6PD
• Product code: ND-1000
• Manufacturer: Wallac Oy – Finland
• Packaging: 960 tests/kit
• Principle of the Test

The assay is based on fluorescence detection. The assay involves the oxidation of glucose-6 minutes at ambient temperature. Copper sulfate is added to slow down the reaction. The  phosphate (G-6-P) substrate to 6-phosphogluconate (6-PG), by the G6PD present in the 
blood spot sample and the concomitant reduction of NADP to NADPH. The blood spot is  allowed to react with the substrate reagent which consists of G-6-P and NADP, for 30  fluorescence is measured using an excitation wavelength of 355 nm and an emission wavelength of 460 nm.

Application: This kit is designed for G6PD deficiency screening in newborn dried blood spots aged 2–4 days, using the VICTOR™ 2D fluorometer. Ideal for medium to low sample volume laboratories and hospitals.

Required Instruments:

• VICTOR™ 2D Fluorometer

• Wallac DBS Puncher or Panthera-Puncher™ 9

• DELFIA® Plateshake Automatic Plate Shaker

Fully Automated Solution

• Product name: GSP® Neonatal G6PD kit
• Product code: 3310-0010
• Manufacturer: Wallac Oy – Finland
• Packaging: 1,152 tests/kit
• Principle of the Test

The GSP® Neonatal G6PD assay is based on the oxidation of glucose-6-phosphate (G-6-P) into 6-phosphogluconate (6-PG) by G6PD enzyme in the sample, with concurrent reduction of NADP+ to NADPH. The dried blood spot is first eluted for 40 minutes in the presence of NADP, followed by a 10-minute reaction with the substrate G-6-P and NADP. Fluorescence is measured using an excitation wavelength of 340 nm and an emission wavelength of 460 nm.

Application: This kit is intended for G6PD deficiency screening in newborn dried blood spots aged 2–4 days, performed on the GSP® platform. Suitable for medium to high sample volume laboratories and hospitals.

Required Instruments:

• GSP® System
• Wallac DBS Puncher or Panthera-Puncher™ 9